WINTON GROUP Ltd Raises Holdings in Halozyme Therapeutics, Inc. $HALO

WINTON GROUP Ltd lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 704.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 60,348 shares of the biopharmaceutical company’s stock after purchasing an additional 52,848 shares during the period. WINTON GROUP Ltd’s holdings in Halozyme Therapeutics were worth $4,723,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Measured Wealth Private Client Group LLC grew its stake in Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 124 shares during the last quarter. Larson Financial Group LLC boosted its holdings in shares of Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 343 shares during the period. MidFirst Bank acquired a new stake in shares of Halozyme Therapeutics in the second quarter valued at approximately $27,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Halozyme Therapeutics during the second quarter worth approximately $28,000. Finally, Quantbot Technologies LP purchased a new position in shares of Halozyme Therapeutics during the second quarter worth approximately $30,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $107.00 on Friday. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The stock has a fifty day moving average price of $93.18 and a 200 day moving average price of $76.75. Halozyme Therapeutics, Inc. has a 1-year low of $61.22 and a 1-year high of $111.15. The company has a market cap of $12.14 billion, a PE ratio of 31.94, a P/E/G ratio of 0.42 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. The firm had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. Halozyme Therapeutics’s quarterly revenue was up 47.7% on a year-over-year basis. During the same period last year, the firm posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 7.98 EPS for the current year.

Insider Activity

In related news, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the transaction, the director directly owned 40,418 shares of the company’s stock, valued at $4,154,970.40. This represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. The trade was a 33.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 32,478 shares of company stock valued at $3,076,604 over the last quarter. Corporate insiders own 2.50% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on HALO. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Weiss Ratings raised shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, August 31st. Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. TD Cowen upped their target price on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a report on Friday, August 7th. Finally, Citizens Jmp increased their target price on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research note on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $91.20.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.